–ASC42 bridging study demonstrated consistent pharmacokinetic profiles between U.S. and Chinese population — ASC42 was safe and well tolerated in Chinese population with only grade 1 adverse events –10 mg and 15 mg once daily doses of ASC42 were selected in combination with pegylated interferon and nucleos(t)ide analogs for Phase II study in patients with chronic hepatitis B HANGZHOU and SHAOXING, China, Aug. 24, 2021 /PRNewswire/ — Ascletis Pharma Inc. (HKEX: 1672) announces today the completion of the bridging study and initiation of Phase II trial of farnesoid X receptor (FXR) agonist ASC42 in China for chronic hepatitis B (CHB) indication. ASC42 is an in-house developed, novel non-steroidal, selective, potent FXR agonist with best-in-class potential.
Subscribe to Updates
Get the latest creative news from FooBar about art, design and business.
Ascletis Announces Completion of the Bridging Study and Initiation of Phase II Trial of FXR Agonist ASC42 in China for Chronic Hepatitis B Indication